Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have been diagnosed with metastatic castration-resistant prostate cancer (a type of prostate cancer that has spread and no longer responds to hormone treatment) and whose treating medical team has assessed them as suitable and prescribed a specific treatment called lutetium (177Lu) vipivotide tetraxetan.
- People who are 18 years of age or older at the time of joining the study.
- People who are willing and able to provide written consent to take part in the study.
Who may not be able to join:
- People for whom lutetium (177Lu) vipivotide tetraxetan is considered medically unsuitable, based on the official prescribing guidelines for this treatment (confirm with trial site).
- People who do not meet the additional requirements set out in the official Italian medicines regulatory documentation (the AIFA Monitoring Form), which may include specific medical contraindications (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.